Terminal β-galactose residues on N-linked glycans (Terminal β-Gal)

Terminal β-galactose residues are carbohydrate motifs located at the non-reducing termini of N-linked glycan chains on glycoproteins. These residues are synthesized in the Golgi apparatus by galactosyltransferases and typically serve as the penultimate sugar, often capped by terminal sialic acids (Moremen et al., 2012, Nature Reviews Molecular Cell Biology). When exposed, these residues function as ligands for various endogenous lectins, most notably the Asialoglycoprotein Receptor (ASGPR) on hepatocytes, which facilitates the rapid clearance of desialylated proteins from circulation (D'Souza & Devarajan, 2015, Journal of Controlled Release). In the immune system, the presence of terminal galactose on the Fc region of IgG is a critical determinant of antibody effector functions, including complement-dependent cytotoxicity (Quast et al., 2015, Journal of Clinical Investigation). Aberrant exposure or increased branching of galactose-terminated glycans is a hallmark of many cancers, where they interact with Galectins to promote tumor cell adhesion, metastasis, and immune evasion (Pinho & Reis, 2015, Nature Reviews Cancer). Consequently, these residues are exploited as targets for liver-specific drug delivery and are the focus of therapeutic strategies involving galectin inhibitors for treating fibrosis and malignancy (Vasta et al., 2012, Current Opinion in Structural Biology).

Other names

Terminal galactoseβ-D-galactosyl residuesAsialo-N-glycansGal-terminated N-glycansGalactosylated N-glycans

Binding to C-type lectins such as the Asialoglycoprotein Receptor (ASGPR) for hepatic uptake; interaction with Galectins to regulate cell signaling and adhesion; serving as a substrate for terminal sialylation by sialyltransferases.